Background: Malnutrition is highly prevalent in older adults and is associated with functional decline, systemic inflammation, and increased mortality. However, its prognostic role in relation to major adverse cardiovascular events (MACE), particularly when considered alongside established cardiovascular risk scores, remains insufficiently defined in geriatric populations. Methods: This retrospective cohort study included 291 adults aged ≥65 years who underwent a comprehensive geriatric assessment at a geriatric outpatient clinic. Nutritional status was evaluated using the Mini Nutritional Assessment—Short Form (MNA-sf). Cardiovascular risk was estimated using the Framingham Risk Score, SCORE2, SCORE2—Older Persons (SCORE2-OP), and LIFE-CVD (version 1). The primary outcome was the occurrence of MACE, and the secondary outcome was all-cause mortality. Multivariable logistic regression and Cox proportional hazards models were used to identify independent predictors of outcomes. Results: During a mean follow-up of 16.9 ± 4.7 months, 43 participants (14.8%) experienced MACE, and 11 (3.8%) died. Malnutrition or risk of malnutrition (MNA-sf < 12), present in 24.1% of participants, was significantly more frequent among those with MACE and those who died. In multivariable analyses, nutritional status remained a consistent independent predictor of both MACE and mortality, whereas commonly used cardiovascular risk scores showed limited or inconsistent associations with outcomes. Conclusions: In older adults, malnutrition assessed by the MNA-sf is a strong and independent predictor of both major adverse cardiovascular events and all-cause mortality, beyond traditional cardiovascular risk scores. These findings underscore the importance of incorporating nutritional status, together with frailty-related parameters, into cardiovascular risk assessment to improve risk stratification in geriatric care.
Fragility fractures constitute a major global health burden and often result from falls. However, clinical care for fragility fractures is currently organized separately from fall prevention services leading to gaps in integrated care delivery. This joint position paper from the European Geriatric Medicine Society, the Fragility Fracture Network, the World Falls Prevention Society, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, the International Osteoporosis Foundation, the European Union of Medical Specialists-Geriatric Medicine Section, and the International Association of Gerontology and Geriatrics–European Region highlights the critical need for integrated falls and fracture prevention, with a focus on evidence-based clinical practice, knowledge dissemination, education, policy strategies, and research. We outline existing guidelines on fall and fracture prevention, with particular emphasis on how fracture risk assessment can be incorporated into fall prevention services and on integrating fall assessment into fracture prevention services. We advocate that future implementation guidelines place greater emphasis on fully integrated models of care. Moreover, training and education programs should be designed to encourage interdisciplinary collaboration among healthcare professionals. Integrated fall and fracture prevention services should be recognized as a public health priority and incorporated into national strategies for healthy aging, supported by adequate, dedicated, and sustainable resources including evidence-based exercise provision. Finally, future research should focus on evaluating the (cost) effectiveness of integrated care models and examining their practical implementation in real-world settings.
Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder with diverse metabolic and hormonal manifestations. Insulin-like peptide 5 (INSL5), a gut-derived hormone of the relaxin/insulin family, is expressed in the central nervous system, colonic and reproductive tissues, but its clinical significance in PCOS remains unclear. This study aimed to evaluate circulating INSL5 levels in PCOS and explore their associations with key hormonal and metabolic parameters. In this prospective cross-sectional study, 45 women with newly diagnosed PCOS and 35 age-matched healthy controls (18–35 years) were evaluated. Clinical characteristics, hormonal profiles, and metabolic markers – including serum anti-Müllerian hormone (AMH) and INSL5 – were assessed. INSL5 levels were measured using enzyme-linked immunosorbent assay (ELISA). Median serum INSL5 levels did not differ significantly between PCOS and control groups (12.5 vs. 15.5 ng/ml; p=0.103). However, within the PCOS group, INSL5 was inversely correlated with body mass index, insulin, HOMA-IR, total and LDL cholesterol, triglycerides, fat mass, and free androgen index, and positively correlated with sex hormone-binding globulin (p<0.05 for all). AMH was significantly higher in the PCOS group and demonstrated a diagnostic cut-off of 5.04 ng/ml (AUC: 0.808; sensitivity: 75.6%; specificity: 74.3%). Although INSL5 did not show diagnostic utility for PCOS, its consistent associations with insulin resistance, androgenic activity, and lipid metabolism suggest a potential role in metabolic regulation. These findings support its relevance as a candidate marker for metabolic phenotyping and warrant further investigation into its physiological role within the PCOS spectrum.